Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
Related Questions
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
What is your approach to the inclusion of simultaneous bariatric surgery at time of liver transplant, especially in MASLD/MASH cirrhotics?
What are your biggest takeaways from the MASH-TAG 2025 conference?
In patients with Met-ALD, would you still offer the same therapeutic/pharmacologic treatments (ex: GIP/GLP-1 agonists, Resmetirom, ex) for management of their disease as in a "pure" MASLD patient?
In a patient with low (or normal) BMI but findings of steatosis on imaging, no cardiometabolic comorbidities, and very elevated CAP scores, what are your next diagnostic and therapeutic steps to identify the cause of their steatosis and subsequent management?
In patients with MASLD and F2–F3 fibrosis, would you initiate Resmetirom even if they are not making active lifestyle changes?
How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?
In patients with MASLD/MASH, do you perform any cardiac testing to create a patient's risk profile, given that cardiac complications are the top cause of morbidity and mortality in this patient population (especially those with advanced fibrosis)?
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
How do you decide which GLP-1s to prescribe for obesity?
